Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 107,117 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Health Outcomes in Young Cisgender Men and Transgender Women (mLab App)

NCT03803683
View directory record Official record
Conditions
HIV Infections
Interventions
mLab App, HIV Prevention Information, HIV Home Tests
Device · Behavioral
Lead sponsor
Rebecca Schnall, RN, MPH, PhD
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 22, 2026, 10:56 PM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents

NCT05372783
View directory record Official record
Conditions
COVID-19
Interventions
STI-9199, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 22, 2026, 10:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Support Needs and Preferences of Family Caregivers of Lung Cancer Patients

NCT00967083
View directory record Official record
Conditions
Lung Cancer
Interventions
Questionnaires/Interviews
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Jamaica, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 22, 2026, 10:56 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The TAIL-PrEP Study

NCT06868641
View directory record Official record
Conditions
HIV Infections
Interventions
TAIL-PrEP for patients discontinuing cab-LA, TAIL-PrEP for patients considering discontinuing cab-LA, TAIL-PrEP for patients considering discontinuing LEN
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 10:56 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure

NCT00744341
View directory record Official record
Conditions
Acute Decompensated Heart Failure; Renal Dysfunction
Interventions
SLV320, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Alameda, California • Banning, California • Inglewood, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2010 · Synced Oct 22, 2026, 10:56 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

NCT03245541
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Durvalumab, Stereotactic Ablative Body Radiotherapy (SABR)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 10:56 PM EDT
Active, not recruiting Not applicable Interventional

CLIP-IT Post-Market Study

NCT06203054
View directory record Official record
Conditions
Left Atrial Appendage Exclusion
Interventions
Penditure™ Left Atrial Appendage (LAA) Exclusion System
Device
Lead sponsor
Medtronic Cardiac Surgery
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Atlanta, Georgia • Chicago, Illinois • Carmel, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 22, 2026, 10:56 PM EDT
Active, not recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Oakland, California • Roseville, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions

NCT00939705
View directory record Official record
Conditions
Healthy
Interventions
topiramate
Drug
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 10, 2011 · Synced Oct 22, 2026, 10:56 PM EDT
Completed No phase listed Observational

Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects

NCT00721994
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis
Interventions
Cormet Hip Resurfacing System
Device
Lead sponsor
Corin
Industry
Eligibility
Not listed
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
5
States / cities
Merritt Island, Florida • Sarasota, Florida • Springfield, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 22, 2026, 10:56 PM EDT
Terminated Phase 1 Interventional

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01076556
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Interventions
Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Rituximab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 22, 2026, 10:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor

NCT01942356
View directory record Official record
Conditions
Acute Cholecystitis, Chronic Cholecystitis
Interventions
TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia, TIVA - Tachycardia, INH - Hypotension, INH - Hypertension, INH - Bradycardia, INH - Tachycardia
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 22, 2026, 10:56 PM EDT
Terminated Phase 2 Interventional Results available

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

NCT04570956
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
Interventions
Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Evanston, Illinois • Rochester, Minnesota • Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Results available

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

NCT03377556
View directory record Official record
Conditions
ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, FANCC Gene Mutation, FANCD2 Gene Mutation, FANCF Gene Mutation, FANCM Gene Mutation, NBN Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, RPA1 Gene Mutation, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
Other · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1151
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 22, 2026, 10:56 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

NCT05548556
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
Placebo, RO7204239
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Orange, California • Aurora, Colorado • Fairway, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction

NCT03802396
View directory record Official record
Conditions
Postoperative Delirium, Postoperative Cognitive Dysfunction
Interventions
CN-105, Placebo
Drug
Lead sponsor
Miles Berger, MD PhD
Other
Eligibility
60 Years and older
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 22, 2026, 10:56 PM EDT
Completed Phase 1 Interventional

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

NCT02576496
View directory record Official record
Conditions
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
Interventions
Tinostamustine
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Jacksonville, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 22, 2026, 10:56 PM EDT
Not listed No phase listed Observational

Outcome Measures Study on an Adult Myoelectric Elbow-Wrist-Hand Orthosis

NCT04900896
View directory record Official record
Conditions
Stroke, Brachial Plexus Injury, Spinal Cord Injuries, Neurological Disease
Interventions
Myoelectric Elbow-Wrist-Hand Orthosis
Device
Lead sponsor
Myomo
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Chardon, Ohio • Edmonds, Washington
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 22, 2026, 10:56 PM EDT
Completed Not applicable Interventional Results available

Improving Communication in the PICU: The Navigate Study

NCT02333396
View directory record Official record
Conditions
Communication
Interventions
PICU Supports, Educational Brochure
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 22, 2026, 10:56 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas

NCT05127096
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
FirstSight blood test
Diagnostic Test
Lead sponsor
CellMax Life
Industry
Eligibility
45 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
15
States / cities
Huntsville, Alabama • Chula Vista, California • Lancaster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 22, 2026, 10:56 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Assess Safety and Efficacy of VAD044 in HHT Patients

NCT05406362
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
VAD044 Part I, VAD044 Part II
Drug
Lead sponsor
Vaderis Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 22, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term Relief From Dentinal Hypersensitivity

NCT02226562
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Potassium nitrate and sodium fluoride, Standard fluoride dentifrice
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 22, 2026, 10:56 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
Interventions
Vimseltinib, Placebo
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
11
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 22, 2026, 10:56 PM EDT
Active, not recruiting Not applicable Interventional

ASCEND CSP IDE Study

NCT06830746
View directory record Official record
Conditions
Heart Failure, Ventricular Arrythmia
Interventions
LBBAP Implant with a CSP ICD Lead
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 99 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Huntsville, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 22, 2026, 10:56 PM EDT